Medistep Health.

How has been the historical performance of Medistep Health.?

Medistep Health has shown significant growth over the past three years, with net sales increasing from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 4.14 Cr. The company has also improved its equity capital and cash flow management during this period.

Answer:<BR>The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 22.98 Cr. Cash flow from financing activities showed a net inflow of 1.00 Cr in Mar'25, compared to an outflow of 7.00 Cr in Mar'24, indicating improved cash management. Overall, Medistep Health has demonstrated robust growth in sales and profitability, alongside an increase in equity and total assets.

Is Medistep Health. overvalued or undervalued?

As of November 13, 2025, Medistep Health is considered very attractive with a PE ratio of 9.37 and an EV to EBIT ratio of 6.86, significantly lower than its peers, indicating it is undervalued despite a strong recent weekly return of 21.88%.

As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. <BR><BR>In comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen.

Why is Medistep Healthcare Ltd falling/rising?

As of 04-Mar, Medistep Healthcare Ltd's stock price is at Rs. 20.90, reflecting a 5.0% decline and marking a new 52-week low. The stock has significantly underperformed against the Sensex and is trading below its moving averages, indicating a bearish trend despite increased investor participation.

As of 04-Mar, Medistep Healthcare Ltd's stock price is falling, currently at Rs. 20.90, which reflects a decrease of Rs. 1.1 or 5.0%. The stock has underperformed against the benchmark Sensex, which has declined by 3.93% over the past week, while Medistep's stock has dropped by 7.11%. Additionally, the stock has experienced a significant decline over the past month, down 8.33%, compared to the Sensex's 5.03% drop.<BR><BR>Today marks a new 52-week and all-time low for the stock, indicating a lack of investor confidence. Furthermore, Medistep Healthcare is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. Although there has been a rise in investor participation, with delivery volume increasing by 150% on March 2, this has not translated into a positive price movement. Overall, the combination of these factors contributes to the stock's current downward trajectory.

Which are the latest news on Medistep Health.?